{"id":26137,"date":"2022-07-26T13:50:42","date_gmt":"2022-07-26T12:50:42","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=26137"},"modified":"2022-07-26T13:50:46","modified_gmt":"2022-07-26T12:50:46","slug":"one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","title":{"rendered":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022"},"content":{"rendered":"\n<p>This report describes the current climate for antimicrobial innovation. It discusses regulatory challenges and<br>opportunities for the approval of new antibiotics in three emerging markets: South Africa, Brazil, and India. <\/p>\n\n\n\n<p>The report is informed by reviews and analyses of several sources, including organizational reports, peer-reviewed<br>literature, and press releases. <\/p>\n\n\n\n<p>Semistructured interviews with experts from international organizations and the scientific and regulatory ecosystem in the three countries were conducted between November 2021 and February 2022 to obtain global and national perspectives on the regulatory landscape for antibiotics.<\/p>\n\n\n\n<p>Download report <a href=\"https:\/\/cddep.org\/wp-content\/uploads\/2022\/06\/Drug-Regulatory-Approvals-and-Opportunities-for-Antimicrobial-Innovation_July-2022.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This report describes the current climate for antimicrobial innovation. It discusses regulatory challenges andopportunities for the approval of new antibiotics in three emerging markets: South Africa, Brazil, and India. The report is informed by reviews and analyses of several sources, including organizational reports, peer-reviewedliterature, and press releases. Semistructured interviews with experts from international organizations and [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":26143,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-26T12:50:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-26T12:50:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"604\" \/>\n\t<meta property=\"og:image:height\" content=\"338\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022\",\"datePublished\":\"2022-07-26T12:50:42+00:00\",\"dateModified\":\"2022-07-26T12:50:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\"},\"wordCount\":105,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\",\"name\":\"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\",\"datePublished\":\"2022-07-26T12:50:42+00:00\",\"dateModified\":\"2022-07-26T12:50:46+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg\",\"width\":604,\"height\":338,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bilans, rapports et recommandations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","og_locale":"fr_FR","og_type":"article","og_title":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2022-07-26T12:50:42+00:00","article_modified_time":"2022-07-26T12:50:46+00:00","og_image":[{"width":604,"height":338,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022","datePublished":"2022-07-26T12:50:42+00:00","dateModified":"2022-07-26T12:50:46+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/"},"wordCount":105,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/","name":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022 - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","datePublished":"2022-07-26T12:50:42+00:00","dateModified":"2022-07-26T12:50:46+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Pill-medical-3D.jpg","width":604,"height":338,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/one-health-trust-report-drug-regulatory-approvals-and-opportunities-for-antimicrobial-innovation-perspectives-from-brazil-india-and-south-africa-july-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Bilans, rapports et recommandations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/"},{"@type":"ListItem","position":4,"name":"One Health Trust report: Drug regulatory approvals and opportunities for antimicrobial innovation, perspectives from Brazil, India and South Africa, July 2022"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-13 00:31:45","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/26137"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=26137"}],"version-history":[{"count":9,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/26137\/revisions"}],"predecessor-version":[{"id":26159,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/26137\/revisions\/26159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/26143"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=26137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=26137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=26137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}